Investor Vector Capital is taking over Corel's creative software; Parallels remains with KKR. Both areas are to operate ...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results